19608-29-8 Usage
Description
17Alpha-propionate, also known as Clascoterone (Winlevi), is an androgen receptor inhibitor developed as a topical cream and solution by Cassiopea for the treatment of androgen-dependent skin disorders. It is a white to almost white powder with the empirical formula C24H34O5 and a molecular weight of 402.5 g/mol. 17Alpha-propionate is practically insoluble in water and has a high affinity for binding to androgen receptors.
Uses
1. Used in Pharmaceutical Industry:
17Alpha-propionate is used as a novel antagonist of androgen receptors for the treatment of acne vulgaris and androgenetic alopecia. It works by competing with androgens for binding to androgen receptors, blocking the androgen receptor signaling cascades that promote acne pathogenesis, such as sebaceous gland proliferation, excess sebum production, and inflammatory pathways.
2. Used in Dermatology:
17Alpha-propionate is used as a first-in-class topical treatment for acne vulgaris in male and female patients aged 12 years and older. It received FDA approval in August 2020 and is being investigated as a novel treatment for androgenetic alopecia.
3. Used in Cosmetic Industry:
17Alpha-propionate is being developed as a topical cream by Cassiopea for androgen-dependent skin disorders, which may include various cosmetic applications targeting skin health and appearance.
Biological Activity
Clascoterone is a high-affinity androgen receptor (AR) antagonist (antiandrogen) that antagonizes testosterone-stimulated transcription activity (in reporter cells) as well as DHT-induced production of lipids and inflammatory cytokines (in human sebocytes) in cultures. When applied topically, clascoterone is as active as cyproterone acetate, and 2-, 3-, and 4-times, respectively, more active than finasteride, flutamide, and progesterone in vivo (local antiandrogenic activity in hamster′s flank organ; 100-400 μg/50 μL acetone/animal).
Safety
Clascoterone(Winlevi) is the only topical acne product with a warning about hypothalamic-pituitary-adrenal (HPA) axis suppression. This may result when Winlevi is used over large surface areas or if use is prolonged. In addition, pediatric patients may be more susceptible. This adverse event was not observed in the pivotal studies or in the long-term open-label extension study. However, it was observed in a small group of patients on Day 14 in a pharmacokinetic study. Normal HPA axis function was observed at follow-up at 4 weeks after end of treatment.
Mode of action
Clascoterone is an androgen receptor inhibitor. The mechanism of action of WINLEVI cream for the topical treatment of acne vulgaris is unknown.
Check Digit Verification of cas no
The CAS Registry Mumber 19608-29-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,9,6,0 and 8 respectively; the second part has 2 digits, 2 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 19608-29:
(7*1)+(6*9)+(5*6)+(4*0)+(3*8)+(2*2)+(1*9)=128
128 % 10 = 8
So 19608-29-8 is a valid CAS Registry Number.
19608-29-8Relevant articles and documents
ENZYMATIC PROCESS FOR OBTAINING 17 ALPHA- MONOESTERS OF CORTEXOLONE AND/OR ITS 9,11- DEHYDRODERIVATIVES
-
Page/Page column 5, (2011/05/03)
The present invention refers to a new enzymatic process for obtaining 17α-monoesters of cortexolone and/or its 9,11-dehydroderivatives starting from the corresponding 17α,21-diesters which comprises an enzymatic alcoholysis reaction. Furthermore, the present invention refers to new crystalline forms of cortexolone 17α-propionate and 9,11-dehydro-cortexolone 17α-butanoate.
